EndoAxis Clinical Team
GLP-1 Receptor Agonists: Mechanism, Efficacy, and Emerging Clinical Concerns
The rapid expansion of GLP-1 receptor agonists from diabetes management into mainstream obesity treatment represents one of the most significant pharmacologic shifts in metabolic medicine in decades. Agents such as semaglutide, tirzepatide, and liraglutide are now prescribed across a widening demographic spectrum, including individuals without overt diabetes. Retatrutide is also part of the GLP peptide family. However, unlike currently approved GLP-based therapies, retatrutide has not yet received approval from the U.S. Food and Drug Administration and is generally classified as a compound intended for “research purposes only.” As such, its full safety profile, long-term effects, and clinical applications have not been fully established through the regulatory review process. While it appears to share many of the same physiological effects, potential side effects, and clinical considerations associated with other GLP-based therapies, the lack of formal regulatory approval means governing bodies have not yet comprehensively evaluated its safety and efficacy. Therefore, its use should be approached with caution and with an understanding that the available evidence is still emerging.
Efficacy is undeniable. Sustained weight reduction of 7–20% total body mass has altered expectations for pharmacologic intervention. Cardiovascular outcome trials demonstrate meaningful reductions in major adverse cardiac events in high-risk populations. Glycemic variability improves. Insulin demand falls.
But these changes impact physiology.
Mechanism: More Than Appetite Suppression
Glucagon-like peptide-1 is an incretin hormone released from intestinal L-cells in response to nutrient intake. Pharmacologic analogs enhance and prolong this signal through several mechanisms:
· Glucose-dependent insulin secretion
· Suppression of glucagon
· Delayed gastric emptying
· Central appetite suppression via hypothalamic and mesolimbic pathways
Importantly, GLP-1 receptors are widely distributed in the body including in cardiac tissue, bone, reproductive organs, and thyroid C-cells. These are not pancreas-specific agents. They amplify a whole-body signal tied to nutrient availability.
When nutrient intake declines chronically, downstream adaptation is predictable.
Caloric Suppression and Adaptive Physiology
GLP-1–induced weight loss occurs primarily through sustained negative energy balance. In many patients, caloric intake drops dramatically, sometimes below what would be recommended in structured medical weight-loss programs.
The body responds to chronic energy deficit with:
Reduced resting energy expenditure beyond predicted mass loss
Decreased peripheral conversion of T4 to T3
- Energy deficit reduces T3 utilization, which impacts mitochondrial ATP production, thermogenesis (heat), and overall basal metabolic rate. When TSH stays “normal”, symptoms of fatigue, cold intolerance, hair thinning, constipation, and plateaued weight loss may occur. This may also elicit reduced energy. This is exaggerated when the degree of weight loss is more than the body can keep up with.
Leptin suppression
- The leptin hormone communicates to the hypothalamus that we are well fed and satiated, we are safe, we can reproduce, and we can burn energy freely. When leptin levels drop too quickly and too low, it can negatively impact thyroid function, hunger signaling (it will increase hunger signaling), and sympathetic tone may decrease (causing more anxiety/hyperstimulation).
- In people that have more metabolic stability coming into GLP use, drops in leptin too quickly can shock the system contributing to improper sex hormone and thyroid signaling, and fatigue.
- Leptin reduction in insulin resistance is likely therapeutic. Rapid leptin decline with aggressive weight loss can trigger adaptive endocrine responses (menstrual changes, thyroid changes). Instead of looking at leptin levels as an absolute value goal it is important to understand this example and dynamic:
- It’s not the absolute leptin value that matters; it’s the magnitude and speed of decline.
- A drop from 45 to 20 ng/mL in an insulin-resistant patient may be beneficial.
- A drop from 16 to 6 ng/mL in a lean woman could meaningfully alter GnRH signaling.
- The hypothalamus responds dynamically.
Altered GnRH pulsations
- GnRH influences FSH and LH signaling. Reduced energy and leptin signaling can slow the GnRH pulsing which may show up as:
- Slower pulse frequency, reduced LH amplitude, shortened luteal phase, reduced progesterone output can lead to anovulation, an/or amenorrhea.
- In females, the impacts of these changes may look like:
- Insulin resistant PCOS: ovulation may improve
- Already cycling women: may cause luteal phase defect/insufficiency
- In males, the impacts of caloric restrictions may show up as
- In metabolically stable males reductions in testosterone levels and/or reduced spermatogenesis
- In males with insulin resistance improved testosterone and/or sperm production
Potential shifts in cortisol signaling
- Sustained caloric restriction may be interpreted as environmental stress, which may lead to elevated basal cortisol, altered diurnal rhythm, and lower DHEA-s levels.
- This may lead to sleep disturbance, increased anxiety, elevated resting heart rate, impaired muscle retention, and increased bone resorption.
These adaptations are physiologic, not pathological. They are survival mechanisms.
However, in patients without overt metabolic disease, particularly younger individuals using GLPs for cosmetic weight loss, the long-term endocrine implications remain insufficiently characterized.
Dose Escalation and Overexposure
Titration protocols were designed to mitigate gastrointestinal and metabolic side effects. Yet in clinical practice, pressures for rapid weight loss frequently drive dose acceleration beyond patient tolerance.
Reported adverse effects include:
- Severe nausea and vomiting
- Persistent gastroparesis
- Biliary disease
- Pancreatitis (rare, but monitored)
- Dehydration and electrolyte imbalance
- Marked loss of lean mass
Emergency department visits related to GLP-1 overdosing have increased in some regions. Compounded formulations, often marketed during supply shortages, raise additional concerns regarding purity, stability, and dosing accuracy.
The pharmacologic potency of these agents warrants the same respect afforded to any hormone-modulating therapy. This is where consideration of starting low and going slow is a wise therapeutic strategy. When the dose increase outweighs the therapeutic benefit, we risk shocking the body in multiple ways, and it cannot keep up metabolically. Meaning, the body cannot handle such quick weight loss physically (loose skin, poor satiety, inability to stabilize blood sugar levels), nor metabolically (inability to maintain or sustain weight loss, realigning thyroid and sex hormone function).
The Clinical Inflection Point
GLP-1 receptor agonists are powerful tools. In insulin-resistant, cardiometabolically high-risk patients, their benefits are substantial.
The emerging question is not whether these drugs work.
It is whether we are pairing them with:
- Structured resistance training
- Adequate protein intake
- Micronutrient oversight
- Endocrine monitoring
- Long-term discontinuation planning
Weight reduction achieved without metabolic restoration may carry downstream consequences. These considerations should be personalized regarding protein/macro levels, activity level, and individual monitoring for hormone function and stabilization.
The next phase of GLP-1 medicine does not only require enthusiasm for options in treatment but layered clinical stewardship and extensive educational discussions with patients regarding dose strategies, and adjunct therapies for optimal metabolic health.
EndoAxis offers insight into endocrine function through testing technology and interpretation, as well as supplements that support optimal endocrine function. Because each person has nuanced patterns and enzyme functions, we are able to offer individualized evaluation and support. Join us next week for the continued discussion on GLP medications and hormone impacts (Part 2)!
